ASPro-PD Ambroxol Trial

The ASPro-PD Phase III Ambroxol trial is currently exploring whether the drug Ambroxol can slow the progression of Parkinson’s Disease.

Ambroxol is an already licensed medicine in many European countries which is used to relieve mucus production in coughs and inflammation in sore throats. 

The trial will involve 330 people with Parkinson’s Disease across approximately 12 clinical centres in the UK. The trial is placebo controlled, meaning half of the participants will receive Ambroxol and half will receive a placebo 'dummy' drug for two years.

All participants in the trial will need to undergo genetic sequencing with PD Frontline before enrolment. Once they have received their genetic results, they may then be eligible for the trial. 

EJS ACT-PD

The Edmund J Safra Accelerating Clinical Trials in Parkinson’s Disease (EJS ACT-PD) project is comprised of over 90 members across the UK who are aiming to improve clinical trials in Parkinson’s Disease.

The members include people with Parkinson’s Disease and care partners so that the project has patient interest in mind.

They are designing a Multi-Arm Multi-Stage (MAMS) trial to find treatments that slow or stop disease progression.

The trial will test several different treatments at once, which are assessed at early interims to see whether or not they are effective. They then decide whether to take these treatments further through the rest of the stages of the trial.

Treatments that don’t show promise are removed and replaced with other potential treatments, meaning the trial process is more efficient.